A South Carolina jury hearing the latest trial over the alleged link between Johnson & Johnson talcum powder products and asbestos-related cancer said Friday it could not decide if J&J was responsible for the mesothelioma that killed a 30-year-old attorney, leading to a mistrial.
The U.S. Food and Drug Administration’s move to dramatically curtail large-scale compounding of lower-cost drugs is stoking fiery debate about benefits for patient safety and possible drug shortages.
As the Seventh Circuit gears up to hear oral arguments Wednesday in a suit against GlaxoSmithKline over the suicide of an attorney who was taking a generic version of the antidepressant Paxil, experts say the end result could be a circuit split that pushes the U.S. Supreme Court to decide whether branded pharmaceutical companies should carry liability for generic versions of their drugs.
A recent Federal Circuit decision applying the rarely-invoked printed matter doctrine to invalidate a respiratory drug patent could give litigants another way to challenge patents and get in patent-eligibility arguments that otherwise can't be made in inter partes reviews, attorneys say.
A Texas jury awarded more than $1.2 million on Thursday evening to a Houston firefighter who said his Cook Inc. vein filter perforated his tissue, finding Cook didn’t properly warn the implanting surgeon about the risks.
At the parties' request, the Federal Circuit on Thursday dismissed Mylan Pharmaceuticals Inc.'s bid to upend a lower court decision upholding the validity of AstraZeneca AB's patent on two diabetes drugs, weeks before oral arguments in the appeal, a sign of a possible settlement.
A Pennsylvania federal judge has cleared Teva Pharmaceuticals Industries Ltd. to use deposition testimony in an antitrust class action over an alleged pay-for-delay scheme for generic versions of cholesterol drug Niaspan, ruling that the pharmaceutical giant had not weaponized information protected by attorney-client privilege.
A wave of venture-backed biotechnology and health care companies are lining up initial public offerings that could price in June, including at least eight that filed plans during the week of May 21, leading more than a dozen IPO prospects set to reignite deal flow in the coming weeks.
The releases of highly effective, highly priced drugs to treat chronic diseases has bred a spate of efforts by activists to disenfranchise drug developers of their patent rights. The Federal Circuit's decision this month in AIDS Healthcare Foundation v. Gilead demonstrates how choosing the wrong venue for your patent challenge can doom it before it even starts, says Nicholas Landau of Bradley Arant Boult Cummings LLP.
When Congress passed the Animal Welfare Act in 1966, it stressed the law was needed because of “the shocking failure of self-policing” by the animal experimentation industry. Yet now, the U.S. Department of Agriculture is considering a return to self-policing — an exceedingly bad idea, says Delcianna Winders, visiting scholar at the Elisabeth Haub School of Law at Pace University.
There are numerous opportunities and pitfalls that lie in store for new associates as they enter BigLaw, yet many of the intricacies of navigating the inner workings of a large law firm are not taught in school, leaving many lawyers to fend for themselves to learn by trial and error. Here, BigLaw veterans reflect on some of the actions incoming attorneys can take to make the best of their early days at a firm.
The former Fisher Phillips employment partner sentenced to life in prison earlier this week for the shooting death of his wife has been hit with a civil lawsuit in Georgia state court by the administrator of his wife’s estate.
The European Union’s new data protection regime went into effect, the U.S. House of Representatives voted to loosen regulations for thousands of community banks and regional lenders, and the U.S. Supreme Court sided with employers in class action arbitration cases. These are some of the stories in corporate legal news you may have missed in the past week.
For those who missed out, here's a look back at the law firms, stories and expert analyses that generated the most buzz on Law360 last week.
Litigants who proffer data obtained from social networking sites like Facebook, Twitter and Instagram must authenticate that data before it will be admitted as evidence. Attorneys with Pepper Hamilton LLP examine decisions from Pennsylvania and other jurisdictions to determine whether courts are imposing a more demanding standard for social media data than other documentary evidence.